ANIP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ANI Pharmaceuticals Inc (ANIP) is not a strong buy for a beginner investor with a long-term horizon at this moment. While the company has shown strong revenue growth and has an upcoming earnings report that could act as a catalyst, the technical indicators are bearish, insider selling has increased significantly, and there is market uncertainty reflected in mixed analyst revisions. Given the investor's preference for long-term stability, it is better to wait for clearer signals or improved financial performance before committing to this stock.
The technical indicators for ANIP are bearish. The MACD histogram is negative and contracting, RSI is neutral at 46.653, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 77.03, with resistance at 79.436 and support at 74.623. This suggests limited upward momentum in the short term.
Strong revenue growth in Q3 2025, up 53.58% YoY.
Upcoming Q4 2023 earnings report with strong EPS and revenue estimates.
Increased visibility from participation in the 44th Annual J.P. Morgan Healthcare Conference.
Guggenheim raised the price target to $124, maintaining a Buy rating.
Insider selling has increased significantly (1679.19% over the last month).
Mixed analyst revisions with more downward adjustments for EPS and revenue estimates in the last three months.
Bearish technical indicators and lack of clear upward momentum.
Net income and EPS declined significantly in Q3 2025, indicating potential profitability challenges.
In Q3 2025, ANI Pharmaceuticals reported a 53.58% YoY increase in revenue to $227.81M. However, net income dropped by -196.82% YoY to $23.79M, and EPS fell by -188.98% YoY to 1.13. Gross margin improved slightly to 49.07%, up 4.72% YoY. While revenue growth is strong, profitability metrics have deteriorated significantly.
Guggenheim recently raised the price target for ANIP to $124 from $115, maintaining a Buy rating. This is based on increased Cortrophin sales estimates and a positive outlook for 2026. However, mixed analyst revisions for EPS and revenue estimates over the last three months reflect market uncertainty.
